RightAnswer Knowledge Solutions Search Results for 112809-51-5

New Search  |  Search Results (112809-51-5)  |  Index of Example Chemical Results Pages
register now
RightAnswer Knowledge Solutions provides access to hundreds of data sources. Our premier and proprietary sources include fully-researched documents from well-established experts in the chemical and HazMat fields.

A search in our system for this chemical would return results – all in one place -- in the following categories from the listed data sources.
  • Chemical Identification
  • Environmental Hazards
  • First Aid/Medical Treatment
  • Handling/Storage/Shipping/Waste Management
  • Personal Protection
  • Physical Hazards/Corrective Response Actions
  • Physical/Chemical Properties
  • Regulatory/Standards/Labels
  • Report Abstracts and Studies
  • Reproductive Risk
  • Toxicology/Health Hazards/Exposure
Example of Acute Exposure data from MEDITEXT.

RightAnswer Proprietary Data Sources:

HAZARDTEXT™ Documentshelp
MEDITEXT® Documentshelp


All Other Data Sources:

CCRIS Documentshelp
DART Documentshelp
ECOTOX Documentshelp
HSDB® Data Bankhelp
LOLI® Listingshelp
REPROTOX® Documentshelp
RTECS® Registryhelp
Shepard's Cataloghelp
MSDSonline®help

ChemID External Links:


Other Government Links Searched via RegsKnowledge:

State Environmental Regulationshelp
CFR Regulationshelp

Example Content from MEDITEXT for 112809-51-5:


Please note: this is an extract of information from a larger document. Full document and details are available by subscription.

ACUTE EXPOSURE INFORMATION

  1. USES: Letrozole is used to treat postmenopausal women with breast cancers.
  1. PHARMACOLOGY: Letrozole is a nonsteroidal competitive inhibitor of aromatase and thus, in postmenopausal women, inhibits conversion of adrenal androgens (primarily androstenedione and testosterone) to estrogens (estrone and estradiol) in peripheral tissues and cancer tissue. As a result, letrozole interferes with estrogen-induced stimulation or maintenance of growth of hormonally responsive (estrogen and/or progesterone receptor positive or receptor unknown) breast cancers.
  1. EPIDEMIOLOGY: Overdose is rare.
  1. WITH THERAPEUTIC USE
    1. COMMON (more than 20%): Hot flashes, arthralgia, flushing, asthenia, edema, bone pain, headache, dizziness, hypercholesterolemia, and increased sweating. OTHER EFFECTS: Nausea, vomiting, diarrhea, anorexia, dyspepsia, abdominal pain, constipation, hypertension, chest pain, rash, alopecia, vaginal discharge, bleeding, and irritation, urinary tract infection, elevated liver enzymes, muscle pain, joint pain, back pain, limb pain, fatigue, insomnia, dyspnea, and cough. Pancytopenia, leukopenia, and peripheral thromboembolic events, such as venous thrombosis, thrombophlebitis, portal vein thrombosis, and pulmonary embolism have rarely been reported in clinical trials and postmarketing reports, however, cause and effect relationships have not been established. Letrozole is classified as pregnancy category X.
  1. WITH POISONING/EXPOSURE
    1. TOXICITY: Overdose data are limited. Overdose effects are anticipated to be an extension of adverse effects following therapeutic doses. In isolated cases of letrozole overdose, the highest single dose of 62.5 mg or 25 tablets did not result in serious adverse effects.
© 2011-2017 RightAnswer.com, Inc. and/or its licensors. All rights reserved. No claim to original U.S. Govt. works.